Risk factors for melanoma development

Melanoma incidence has risen over the last 30 years; however, whether this increase is entirely genuine or caused, in part, by increased screening, needs to be addressed. A large number of nevi is the strongest risk factor for melanoma across all Caucasian populations. Number of nevi is heritable with 60% of the variation in their number attributed to additive genetic effects. Fair hair and skin is also a heritable risk factor but the magnitude of the risk is much smaller than nevi. There are different ‘at-risk’ phenotypes leading to melanoma: high number of nevi or alternatively sun damage with solar keratoses, and these two phenotypes are usually mutually exclusive. This suggests different pathways leading to melanoma. Sun exposure is linked to melanoma with an increased melanoma incidence with decreasing latitude. However, this association is very complex and is not dose dependent. Similar to all cancers, melanoma can cluster in families. Between 20 and 40% of melanoma-prone families have mutations in ...

[1]  T. Spector,et al.  Pigmentation and Vitamin D Metabolism in Caucasians: Low Vitamin D Serum Levels in Fair Skin Types in the UK , 2009, PloS one.

[2]  J. Malvehy,et al.  Genome-wide association study identifies three loci associated with melanoma risk , 2009, Nature Genetics.

[3]  T. Spector,et al.  Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi , 2009, Nature Genetics.

[4]  K. Pienta Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. , 2009, Urology.

[5]  Tim K. Lee,et al.  Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls , 2009, International journal of epidemiology.

[6]  R. Souchon,et al.  Actual management of ductal carcinoma in situ of the breast , 2009, Archives of Gynecology and Obstetrics.

[7]  Andreas Ziegler,et al.  A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes , 2009, International journal of cancer.

[8]  N. Hayward,et al.  Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas , 2008, Melanoma research.

[9]  S. Steinberg,et al.  Corrigendum: ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma , 2008, Nature Genetics.

[10]  Sabine Siesling,et al.  Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. , 2008, European journal of cancer.

[11]  P. Pharoah Shedding light on skin cancer , 2008, Nature Genetics.

[12]  Kari Stefansson,et al.  ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma , 2008, Nature Genetics.

[13]  R. Kirsner,et al.  Melanoma in Hispanic and black Americans. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[14]  Nils Homer,et al.  Common sequence variants on 20q11.22 confer melanoma susceptibility , 2008, Nature Genetics.

[15]  F. Sera,et al.  MC1R variants, melanoma and red hair color phenotype: A meta‐analysis , 2008, International journal of cancer.

[16]  V. Siskind,et al.  Changes in the incidence of cutaneous melanoma in the west of Scotland and Queensland, Australia: hope for health promotion? , 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[17]  M. Pollán,et al.  Do sex and site matter? Different age distribution in melanoma of the trunk among Swedish men and women , 2008, The British journal of dermatology.

[18]  F. Langmark,et al.  Population‐based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas , 2008, Genes, chromosomes & cancer.

[19]  G. Botti,et al.  Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma , 2007, The British journal of dermatology.

[20]  M. Janssen-Heijnen,et al.  Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. N. Newton Bishop,et al.  Genetics: what advice for patients who present with a family history of melanoma? , 2007, Seminars in oncology.

[22]  M. Ringnér,et al.  Genomic profiling of malignant melanoma using tiling-resolution arrayCGH , 2007, Oncogene.

[23]  T. Spector,et al.  Nevus Size and Number Are Associated with Telomere Length and Represent Potential Markers of a Decreased Senescence In vivo , 2007, Cancer Epidemiology Biomarkers & Prevention.

[24]  J. Aitken,et al.  Diagnosis and management costs of suspicious skin lesions from a population-based melanoma screening programme , 2007, Journal of medical screening.

[25]  S. Puig,et al.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents , 2006, Journal of Medical Genetics.

[26]  D. Pinkel,et al.  MC1R Germline Variants Confer Risk for BRAF-Mutant Melanoma , 2006, Science.

[27]  S. Ariyan,et al.  Gender-Related Differences in Outcome for Melanoma Patients , 2006, Annals of surgery.

[28]  Arjun Chanmugam,et al.  Cutaneous malignant melanoma. , 2006, Mayo Clinic proceedings.

[29]  J. Aitken,et al.  Trends for in situ and Invasive Melanoma in Queensland, Australia, 1982–2002 , 2006, Cancer Causes & Control.

[30]  P. Autier Cutaneous malignant melanoma: facts about sunbeds and sunscreen , 2005, Expert review of anticancer therapy.

[31]  C. Garbe,et al.  Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior , 2005, International journal of cancer.

[32]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. , 2005, European journal of cancer.

[33]  J. Coebergh,et al.  A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. , 2005, European journal of cancer.

[34]  Lisa M. Schwartz,et al.  Skin biopsy rates and incidence of melanoma: population based ecological study , 2005, BMJ : British Medical Journal.

[35]  J. Fridlyand,et al.  RESPONSE: Re: Determinants of BRAF Mutations in Primary Melanomas , 2005 .

[36]  M. Purdue Re: Determinants of BRAF mutations in primary melanomas. , 2005, Journal of the National Cancer Institute.

[37]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. , 2005, European journal of cancer.

[38]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. , 2005, European journal of cancer.

[39]  E. de Vries,et al.  Lower incidence rates but thicker melanomas in Eastern Europe before 1992: a comparison with Western Europe. , 2004, European journal of cancer.

[40]  B. Karlan,et al.  Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Holly,et al.  Incidence of cutaneous melanoma among non-Hispanic Whites, Hispanics, Asians, and Blacks: an analysis of California Cancer Registry data, 1988-93 , 1997, Cancer Causes & Control.

[42]  Ajay N. Jain,et al.  Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.

[43]  V. Bataille,et al.  Genetic epidemiology of melanoma. , 2003, European journal of cancer.

[44]  N. Hayward,et al.  Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. , 2003, Journal of the National Cancer Institute.

[45]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[46]  Florence Demenais,et al.  Geographical variation in the penetrance of CDKN2A mutations for melanoma. , 2002, Journal of the National Cancer Institute.

[47]  R. Willemze,et al.  Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. , 2001, The Journal of investigative dermatology.

[48]  J. Barrett,et al.  Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. , 2001, The Journal of investigative dermatology.

[49]  R. MacKie,et al.  Development of melanocytic nevi in the first three years of life. , 2000, Journal of the National Cancer Institute.

[50]  Lisa M. Schwartz,et al.  Are increasing 5-year survival rates evidence of success against cancer? , 2000, JAMA.

[51]  P Sasieni,et al.  Genetics of risk factors for melanoma: an adult twin study of nevi and freckles. , 2000, Journal of the National Cancer Institute.

[52]  J Cuzick,et al.  Solar keratoses: A risk factor for melanoma but negative association with melanocytic naevi , 1998, International journal of cancer.

[53]  J. Cuzick,et al.  The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. , 1998, British Journal of Cancer.

[54]  D. Easton,et al.  Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: Systematic overview of 10 case‐control studies , 1995 .

[55]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[56]  D. Bishop,et al.  Family studies in melanoma: identification of the atypical mole syndrome (AMS) phenotype , 1994, Melanoma research.

[57]  P. Hersey,et al.  An analysis of a melanoma epidemic , 1993, International journal of cancer.